The short version of pentapeptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-03. Anything still debated is marked as such rather than presented as settled.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
=== Analogues === In addition to deupsilocin, Helus Pharma has also patented other deuterated psilocin isotopologues. Other deuterated drugs related to deupsilocin include the deuterated dimethyltryptamine (DMT) isotopologues deudimethyltryptamine (HLP004; CYB004; DMT-d10; deudimethyltryptamine) and SPL028 (D2-DMT) and the deuterated phenethylamine HLP005 (CYB005).
== Combination Therapy - Antibacterial == Photodynamic/photothermal combination therapy combines the mechanisms of ROS production and heat generation into one treatment for a heightened effect on the target bacterial cells. In many cases, this can be done with a single compound or nanomaterial (phototherapeutic agent) and wavelength.
== System overview == In vertebrates, limb position and velocity are encoded by muscle spindle group Ia afferents responding to muscle length and velocity and muscle spindle group II afferents responding mainly to muscle length. There is a similar division of encoding in invertebrates; different subgroups of neurons of the chordotonal organ encode limb position and velocity. Load on a limb is signaled by Golgi tendon organs: type Ib afferents. These proprioceptors respond to the force a muscle is exerting. Similarly, invertebrates have a mechanism to determine limb load: the campaniform sensilla. These proprioceptors are active when a limb experiences resistance. A third role for proprioceptors is to determine when a joint is at a specific position. In vertebrates, this is accomplished by Ruffini endings and Pacinian corpuscles. These proprioceptors are activated when the joint is at a threshold position, usually at the extremes of joint position. Invertebrates use hair plates to accomplish this; a field of bristles located within joints that detects the relative movement of limb segments through the deflection of the associated cuticular hairs.
== Production == Ketone bodies are produced mainly in the mitochondria of liver cells, and synthesis can occur in response to an unavailability of blood glucose, such as during fasting. Other cells, e.g. human astrocytes, are capable of carrying out ketogenesis, but they are not as effective at doing so. Ketogenesis occurs constantly in a healthy individual. Ketogenesis in healthy individuals is ultimately under the control of the master regulatory protein AMPK, which is activated during times of metabolic stress, such as carbohydrate insufficiency. Its activation in the liver inhibits lipogenesis, promotes fatty acid oxidation, switches off acetyl-CoA carboxylase, turns on malonyl-CoA decarboxylase, and consequently induces ketogenesis. Ethanol is a potent AMPK inhibitor and therefore can cause significant disruptions in the metabolic state of the liver, including halting of ketogenesis, even in the context of hypoglycemia. Ketogenesis takes place in the setting of low glucose levels in the blood, after exhaustion of other cellular carbohydrate stores, such as glycogen. It can also take place when there is insufficient insulin (e.g. in type 1 (and less commonly type 2) diabetes), particularly during periods of "ketogenic stress" such as intercurrent illness. The production of ketone bodies is then initiated to make available energy that is stored as fatty acids. Fatty acids are enzymatically broken down in β-oxidation to form acetyl-CoA.
=== Malta === The Parliament of Malta consists of the president of Malta and the House of Representatives of 69 members (article 51 of the Constitution), referred to as "members of Parliament" (article 52(1) of the Constitution). When appointed from outside the House, the speaker is also considered a member of the Parliament. The Constitution lists the qualifications and disqualifications from serving as a member of Parliament. Privileges of members of Parliament and their Code of Ethics are laid out in the House of Representatives (Privileges and Powers) Ordinance.
Sources: en.wikipedia.org
P2Y purinoceptor 13 is a protein that in humans is encoded by the P2RY13 gene. The product of this gene, P2Y13, belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is activated by ADP. Two transcript variants encoding the same protein have been identified for this gene.
Chin J. B., ed. Control of Communicable Diseases Manual. 17th ed. APHA [American Public Health Association] Press; 2000. ISBN 978-0-87553-189-2 Red Book: 2009 Report of the Committee on Infectious Diseases. 2009. American Academy of Pediatrics. 28th ed. ISBN 978-1-58110-306-9 Centers for Disease Control and Prevention. CDC Works 24/7. Retrieved on August 4, 2009.
Province of German Bohemia (Provinz Deutschböhmen), the regions of northern and western Bohemia; proclaimed a constitutive state (Land) of the German-Austrian Republic with Reichenberg (Liberec) as capital, administered by a Landeshauptmann (state captain), consecutively: Rafael Pacher (1857–1936), 29 October – 6 November 1918, and Rudolf Ritter von Lodgman von Auen (1877–1962), 6 November – 16 December 1918 (the last principal city was conquered by the Czech army but he continued in exile, first at Zittau in Saxony and then in Vienna, until 24 September 1919). Province of the Sudetenland (Provinz Sudetenland), the regions of northern Moravia and Austrian Silesia; proclaimed a constituent state of the German-Austrian Republic with Troppau (Opava) as capital, governed by a Landeshauptmann: Robert Freissler (1877–1950), 30 October – 18 December 1918. This province's boundaries do not correspond to what would later be called the Sudetenland, which contained all the German-speaking parts of the Czech lands. Bohemian Forest Region (Böhmerwaldgau), the region of Bohemian Forest/South Bohemia; proclaimed a district (Kreis) of the existing Austrian Land of Upper Austria; administered by Kreishauptmann (district captain): Friedrich Wichtl (1872–1922) from 30 October 1918. German South Moravia (Deutschsüdmähren), proclaimed a District (Kreis) of the existing Austrian land Lower Austria, administered by a Kreishauptmann: Oskar Teufel (1880–1946) from 30 October 1918. The U.S.
In the Georgian period, many excellent examples of the period's houses were built in Billericay. One of those remaining today is Burghstead Lodge in High Street, which used to house the library. The Town Hall was built in 1830 at 94 High Street. The Billericay Poor Law Union was created in 1835 to serve the town and several surrounding parishes. It built a workhouse in 1840 on Norsey Road. Parts of this building were later incorporated into St Andrew's Hospital. The population of the town in the 1841 census was 1,824. The railway arrived in Billericay in 1889; the station is situated on a branch line from the Great Eastern Main Line between Shenfield and Southend-on-Sea. In 1899, Billericay's market, the reason for the town's establishment is recorded for the last time, though there were short-lived revivals.
Sources: en.wikipedia.org
=== Performing arts === The Coastal Credit Union Music Park at Walnut Creek hosts major international touring acts. In 2011, the Downtown Raleigh Amphitheater opened (now sponsored as the Red Hat Amphitheater), which hosts numerous concerts primarily in the summer months. An additional amphitheater sits on the grounds of the North Carolina Museum of Art, which hosts a summer concert series and outdoor movies. Nearby Cary is home to the Koka Booth Amphitheatre which hosts additional summer concerts and outdoor movies, and serves as the venue for regularly scheduled outdoor concerts by the North Carolina Symphony based in Raleigh. During the North Carolina State Fair, Dorton Arena hosts headline acts. The private Lincoln Theatre is one of several clubs in downtown Raleigh that schedules many concerts throughout the year in multiple formats (rock, pop, country). The Duke Energy Center for the Performing Arts complex houses the Raleigh Memorial Auditorium, the Fletcher Opera Theater, the Kennedy Theatre, and the Meymandi Concert Hall. In 2008, a new theatre space, the Meymandi Theatre at the Murphey School, was opened in the restored auditorium of the historic Murphey School. Theater performances are also offered at the Raleigh Little Theatre, Long View Center, Ira David Wood III Pullen Park Theatre, and Stewart and Thompson Theaters at North Carolina State University.
==== MeSH D06.472.610 – pancreatic hormones ==== MeSH D06.472.610.469 – glucagon precursors MeSH D06.472.610.469.500 – glucagon MeSH D06.472.610.575 – insulin MeSH D06.472.610.575.408 – insulin, isophane MeSH D06.472.610.575.532 – insulin, long-acting MeSH D06.472.610.575.788 – proinsulin MeSH D06.472.610.575.788.250 – c-peptide MeSH D06.472.610.700 – pancreatic polypeptide MeSH D06.472.610.780 – somatostatin
Drug Information Association (DIA) EVENT: DIA/FDA Orphan Drug Designation Workshop November 2010 Archived 2010-10-28 at the Wayback Machine European Commission - The Orphan drugs strategy List of European Orphan Drugs USA Food and Drug Administration: The Orphan Drug Act (as amended) US FDA List of Orphan Designations and Approvals
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.